Further clinical trial planned for Valneva’s COVID-19 vaccine candidate
Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The new VLA2001-304 s...
Insights into the latest developments in CDMO services and manufacturing.
Continue readingExpert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingExploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement